Medtronic
 
 

Activa® Therapy

Activa Parkinson’s Control Therapy — Worldwide Clinical Study

Study Results1
Activa Parkinson’s Control Therapy was shown to increase "on" time—periods of good motor function and symptom relief—by an average of more than 6 hours per day at 12 months post implant (includes only patient data that were fully verified against medical records):

*Includes only patient data that were fully verified against medical records.Percentages have been rounded to the nearest whole percentage.

In the Medtronic clinical study, Activa Parkinson’s Control Therapy reduced dyskinetic "on" time by an average of 2.8 hours in STN patients and 4.2 hours in GPi patients1 (includes only patient data that were fully verified against medical records):

References
  1. Medtronic Activa Therapy Clinical Summary 2002, UC19990178 EN.
  2. Data on file at Medtronic.

Additional Information

  • Results
  • Study Design
  • Register for updates on Medtronic Activa Therapy
  • Visit WeMove.org to learn more about movement disorders education and treatment information
  • Contact Medtronic Activa Physician Services